Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how TG Therapeutics presented additional Phase 3 trial data indicating that ublituximab improves disability and quality of life in people with MS.
He also reads “Why I’m Giving 3 MS Medications Another Try” from Ed Tobias’ column, “The MS Wire.”
===================================
=====================================